{"denoms":[{"counts":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"92"},{"groupId":"BG003","value":"226"}],"units":"Participants"}],"groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Arm A (Lenalidomide; Phase II)"},{"description":"Patients receive lenalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"BG001","title":"Arm A (Lenalidomide; Phase III)"},{"description":"Patients undergo observation until progression to symptomatic myeloma.","id":"BG002","title":"Arm B (Observation; Phase III)"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"36","upperLimit":"83","value":"62"},{"groupId":"BG001","lowerLimit":"31","upperLimit":"82","value":"63"},{"groupId":"BG002","lowerLimit":"33","upperLimit":"96","value":"64"},{"groupId":"BG003","lowerLimit":"31","upperLimit":"86","value":"64"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"46"},{"groupId":"BG003","value":"118"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"46"},{"groupId":"BG003","value":"108"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"6"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"81"},{"groupId":"BG003","value":"205"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"15"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"37"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"68"},{"groupId":"BG003","value":"177"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"10"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"All registered patients in phase II portion and randomized patients in phase III portion"}